The US Food and Drug Administration (FDA) approved the first at-home test for syphilis for sale without a prescription. The test, manufactured by NOWDiagnostic and called First To Know Syphilis Test, arrives amid an 80% increase in cases in the US between 2018 and 2022, from 115 000 to 207 000 cases.
Risultati per: Scompenso Cardiaco. Gestione in MG dalla diagnosi al follow-up
Questo è quello che abbiamo trovato per te
Cavalli e cani come terapia, anche per gestione stress veterani
I risultati del progetto Iss “Veterani in Sella”
Cavalli e cani come terapia, anche per gestione stress veterani
I risultati del progetto Iss “Veterani in Sella”
Immunoterapia, al Gemelli la gestione delle complicanze endocrinologiche
Tra gli effetti indesiderati le disfunzioni di tiroide e ipofisi
Shortfalls in Follow-up Albuminuria Quantification After an Abnormal Result on a Urine Protein Dipstick Test
Annals of Internal Medicine, Ahead of Print.
Shortfalls in Follow-up Albuminuria Quantification After an Abnormal Result on a Urine Protein Dipstick Test
Annals of Internal Medicine, Ahead of Print.
Symptom-Triggered Testing Speeds Up Diagnosis of Aggressive Ovarian Cancer
Symptoms such as abdominal bloating and pain have been a signal to UK and US clinicians to perform diagnostic tests for ovarian cancer. If the results are abnormal, patients in the UK may be fast-tracked for a referral within 2 weeks, despite a lack of clear evidence on how effective this is for women with aggressive ovarian cancer.
Role of Clinician Specialty in Picking Up PrEP
HIV prevention remains a major public health challenge. In 2019, after years of new HIV diagnoses hovering around 38 000 individuals in the US per year, agencies across the US Department of Health and Human Services developed the Ending the HIV Epidemic in the US plan to reduce new HIV diagnoses by 90% by 2030. With setbacks from converging pandemics, in 2021 new infections hovered at 36 000. Thus, finding ways to optimize HIV prevention, including strategies such as pre-exposure prophylaxis (PrEP), is urgent.
Half-Dose Tenecteplase or Primary Percutaneous Coronary Intervention in Older Patients With ST-Elevation Myocardial Infarction: STREAM-2 1-Year Mortality Follow-Up
Circulation, Volume 150, Issue 14, Page 1151-1153, October 1, 2024.
Linee guida per la gestione del carcinoma epatocellulare negli adulti
Nuove linee guida per la gestione cardiovascolare nella chirurgia non cardiaca
Tumori al seno, diagnosi in ritardo per il 20% delle immigrate. Il 39% non esegue la mammografia
Per l’86% degli oncologi sono troppe le disparità di accesso alle cure
Tumori al seno, diagnosi in ritardo per il 20% delle immigrate
Per 86% oncologi sono troppe le disparità di accesso alle cure
Performance and Safety of the Extravascular Implantable Cardioverter-Defibrillator Through Long-Term Follow-Up: Final Results From the Pivotal Study
Circulation, Ahead of Print. Background: Substernal lead placement of the extravascular implantable cardioverter-defibrillator (EV ICD) permits both defibrillation at thresholds similar to those seen with transvenous ICDs and effective antitachycardia pacing (ATP), while avoiding the vasculature and associated complications. The global Pivotal study has shown the EV ICD system to be safe and effective through 6 months, but long-term experience has yet to be published. We aim to report the performance and safety of the EV ICD system throughout the study.Methods: The EV ICD Pivotal study was a prospective, global, single-arm, pre-market clinical study. Individuals with a class I or IIa indication for a single-chamber ICD per guidelines were enrolled. Freedom from major system- or procedure-related complications, as well as appropriate and inappropriate therapy rates, were assessed through 3 years using the Kaplan-Meier method. Anti-tachycardia pacing success was calculated using simple proportions.Results: An implant was attempted in 316 patients [25.3% female, 53.8±13.1 years old, 81.6% primary prevention, LVEF 38.9%±15.4%]. Of 299 patients with a successful implant, 24 experienced 82 spontaneous arrhythmic episodes that were appropriately treated with either ATP only (38, 46.3%), shock only (34, 41.5%), or both (10, 12.2%) for a Kaplan-Meier-estimated rate of first any appropriate therapy of 9.2% at 3 years. Antitachycardia pacing was successful in 77.1% (37/48) of episodes, and ATP usage significantly increased from discharge to last follow-up visit (P
L'infertilità non è una colpa, i consigli per affrontare la diagnosi
Il 22 settembre si celebra la Giornata nazionale di informazione
Diagnosi di Alzheimer: dai biomarcatori di resilienza all’analisi del linguaggio
La ricerca sulla comprensione e sulla gestione di questa malattia neurodegenerativa si apre ai fattori di protezione e allo screening con l’intelligenza artificiale